Revenue Growth Leaders
PEN is part of our revenue growth leaders stock screen, indicating it has strong recent and multi-year revenue growth.
PENUMBRA INC (PEN) Stock Price & Overview
NYSE:PEN • US70975L1070
Current stock price
332.21 USD
+5.21 (+1.59%)
At close:
332.21 USD
0 (0%)
After Hours:
The current stock price of PEN is 332.21 USD. Today PEN is up by 1.59%. In the past month the price decreased by -0.59%. In the past year, price increased by 10.82%.
PEN Key Statistics
52-Week Range221.26 - 362.41
Current PEN stock price positioned within its 52-week range.
1-Month Range326.58 - 337.76
Current PEN stock price positioned within its 1-month range.
- Market Cap
- 13.062B
- P/E
- 86.51
- Fwd P/E
- 65.18
- EPS (TTM)
- 3.84
- Dividend Yield
- N/A
PEN Stock Performance
Today
+1.59%
1 Week
-0.06%
1 Month
-0.59%
3 Months
-7.53%
Longer-term
6 Months +31.31%
1 Year +10.82%
2 Years +69.09%
3 Years +16.93%
5 Years +8.57%
10 Years +509.56%
PEN Stock Chart
PEN Stock Screens
PEN currently appears in the following ChartMill screener lists.
PEN Technical Analysis
ChartMill assigns a technical rating of 4 / 10 to PEN. When comparing the yearly performance of all stocks, PEN turns out to be only a medium performer in the overall market: it outperformed 41.12% of all stocks.
Chartmill TA Rating
Chartmill Setup Rating
PEN Fundamental Analysis
ChartMill assigns a fundamental rating of 7 / 10 to PEN. PEN has outstanding health and profitabily ratings, belonging to the best of the industry. This is a solid base for any company.
Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
PEN Earnings
On February 25, 2026 PEN reported an EPS of 1.18 and a revenue of 385.38M. The company beat EPS expectations (5.02% surprise) and beat revenue expectations (4.03% surprise).
Next Earnings DateMay 5, 2026
Last Earnings DateFeb 25, 2026
PeriodQ4 / 2025
EPS Reported$1.18
Revenue Reported385.385M
EPS Surprise 5.02%
Revenue Surprise 4.03%
PEN Forecast & Estimates
22 analysts have analysed PEN and the average price target is 375.96 USD. This implies a price increase of 13.17% is expected in the next year compared to the current price of 332.21.
For the next year, analysts expect an EPS growth of 32.74% and a revenue growth 14.81% for PEN
Analysts
Analysts70
Price Target375.96 (13.17%)
EPS Next Y32.74%
Revenue Next Year14.81%
PEN Groups
Sector & Classification
PEN Financial Highlights
Over the last trailing twelve months PEN reported a non-GAAP Earnings per Share(EPS) of 3.84. The EPS increased by 33.8% compared to the year before.
Income Statements
Revenue(TTM)1.40B
Net Income(TTM)177.69M
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 12.66% | ||
| ROA | 9.73% | ||
| ROE | 12.45% | ||
| Debt/Equity | 0.01 |
Chartmill High Growth Momentum
EPS Q2Q%21.65%
Sales Q2Q%22.14%
EPS 1Y (TTM)33.8%
Revenue 1Y (TTM)17.5%
PEN Ownership
Ownership
Inst Owners94.76%
Shares39.32M
Float37.95M
Ins Owners2.95%
Short Float %6.42%
Short Ratio3.47
PEN Latest News, Press Relases and Analysis
6 days ago - By: Chartmill
PEN Competitors/Peers
The largest stocks on the US markets in the "Health Care Equipment" sub-industry
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 14.59 | 161.117B | ||
| ISRG | INTUITIVE SURGICAL INC | 41.46 | 160.285B | ||
| SYK | STRYKER CORP | 21.78 | 125.349B | ||
| BSX | BOSTON SCIENTIFIC CORP | 18.6 | 88.457B | ||
| EW | EDWARDS LIFESCIENCES CORP | 27.06 | 45.956B | ||
| IDXX | IDEXX LABORATORIES INC | 39.06 | 45.191B | ||
| BDX | BECTON DICKINSON AND CO | 11.4 | 44.616B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 13.81 | 32.972B | ||
| RMD | RESMED INC | 18.08 | 32.227B | ||
| DXCM | DEXCOM INC | 24.93 | 24.092B | ||
| ZBH | ZIMMER BIOMET HOLDINGS INC | 10.97 | 17.942B | ||
| PODD | INSULET CORP | 29.86 | 13.321B |
Related stock screener links
View all stocks in the Health Care Equipment Industry | View all stocks in the Health Care Sector | View all stocks on the New York Stock Exchange Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find more growth stocks the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About PEN
Company Profile
Penumbra, Inc. is a thrombectomy company, which designs, develops, manufactures, and markets innovative medical products. The company is headquartered in Alameda, California and currently employs 4,700 full-time employees. The company went IPO on 2015-09-18. The firm's broad portfolio, which includes computer assisted vacuum thrombectomy (CAVT), centers on removing blood clots from head-to-toe. The company focuses on developing, manufacturing and marketing novel products for use by specialist physicians and healthcare providers to drive improved clinical and health outcomes. Some of the conditions it focuses on are Pulmonary Embolism, Deep Vein Thrombosis, Acute Limb Ischemia, Ischemic Stroke, Acute Coronary Syndrome, and Clot associated with Arteriovenous Graft or Fistula. The firm sells its products to healthcare providers primarily through its direct sales organization in the United States, Europe, Canada and Australia, as well as through distributors in select international markets.
Company Info
IPO: 2015-09-18
PENUMBRA INC
One Penumbra Place
Alameda CALIFORNIA 94502 US
CEO: Adam Elsesser
Employees: 4700
Phone: 13025310855
PENUMBRA INC / PEN FAQ
What does PENUMBRA INC do?
Penumbra, Inc. is a thrombectomy company, which designs, develops, manufactures, and markets innovative medical products. The company is headquartered in Alameda, California and currently employs 4,700 full-time employees. The company went IPO on 2015-09-18. The firm's broad portfolio, which includes computer assisted vacuum thrombectomy (CAVT), centers on removing blood clots from head-to-toe. The company focuses on developing, manufacturing and marketing novel products for use by specialist physicians and healthcare providers to drive improved clinical and health outcomes. Some of the conditions it focuses on are Pulmonary Embolism, Deep Vein Thrombosis, Acute Limb Ischemia, Ischemic Stroke, Acute Coronary Syndrome, and Clot associated with Arteriovenous Graft or Fistula. The firm sells its products to healthcare providers primarily through its direct sales organization in the United States, Europe, Canada and Australia, as well as through distributors in select international markets.
What is the current price of PEN stock?
The current stock price of PEN is 332.21 USD. The price increased by 1.59% in the last trading session.
Does PENUMBRA INC pay dividends?
PEN does not pay a dividend.
What is the ChartMill technical and fundamental rating of PEN stock?
PEN has a ChartMill Technical rating of 4 out of 10 and a ChartMill Fundamental rating of 7 out of 10.
Should I buy PEN stock?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on PEN.
What is PENUMBRA INC worth?
PENUMBRA INC (PEN) has a market capitalization of 13.06B USD. This makes PEN a Large Cap stock.
Can you provide the short interest for PEN stock?
The outstanding short interest for PENUMBRA INC (PEN) is 6.42% of its float.